For the second quarter of FY2023 ending June 30, 2023, WARBY PARKER ($NYSE:WRBY) reported total revenue of USD 166.1 million, an 11.0% increase year-over-year. Additionally, the company reported a net income of USD -15.9 million, a marked improvement from its -32.2 million loss in the same quarter of the previous year.
On Wednesday, WARBY PARKER reported positive financial earnings for Q2 of FY2023. The stock opened at $15.6 and closed at $13.9, down by 3.5% from the prior closing price of 14.4. The strong financial performance in Q2 is a testament to the success of WARBY PARKER’s business strategy.
Its focus on providing affordable, high-quality eyewear and its commitment to using technology to enhance customer experience is paying off in terms of both customer satisfaction and financial growth. All things considered, these are promising financial results for WARBY PARKER and suggest that the company is on track for continued success in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Warby Parker. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Warby Parker. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Warby Parker. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Warby Parker are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
As GoodWhale, we conducted an analysis of WARBY PARKER‘s financials and were pleased to discover a high health score of 8/10 with regards to cashflows and debt. This suggests that WARBY PARKER is in a strong position to sustain future operations even in times of crisis. Furthermore, our Star Chart showed that WARBY PARKER is strong in growth, medium in asset, profitability and weak in dividend. Based on our analysis, we classified WARBY PARKER as a ‘cheetah’. This company has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Some potential investors who may be interested in this type of company would be those who are looking for rapid growth but who are also willing to accept the increased risk that comes with it. More…
Risk Rating Analysis
Star Chart Analysis
In the world of ophthalmology, there are many companies that compete for market share. Warby Parker Inc is one such company. Founded in 2010, Warby Parker is an online retailer that sells prescription eyeglasses and sunglasses. The company has been successful in taking market share from its competitors, due in part to its focus on providing high-quality products at a lower price point than its competitors. Xvivo Perfusion AB, Kangji Medical Holdings Ltd, and Formosa Optical Technology Co Ltd are all companies that compete with Warby Parker in the ophthalmology space. Each company has its own strengths and weaknesses, and each is vying for a share of the market. Warby Parker has been successful in taking market share from its competitors, and it looks poised to continue to do so in the future.
– Xvivo Perfusion AB ($LTS:0RKL)
Xvivo Perfusion AB is a Sweden-based company engaged in the development and commercialization of perfusion systems for use in organ transplants. The Company’s products include the Xvivo Perfusion System, a portable, self-contained perfusion system that provides oxygenated and nutrients to organs during transport; the Xvivo Perfusion System XPS, a compact, disposable pump designed for single use; and the Xvivo Perfusion System XPS2, a compact, disposable pump with two channels for dual use. In addition, the Company offers the Xvivo Perfusion System XPS3, a compact, disposable pump with three channels for triple use.
– Kangji Medical Holdings Ltd ($SEHK:09997)
Kangji Medical Holdings Ltd is a medical device company that develops, manufactures, and markets minimally invasive products used in various surgical procedures. The company has a market cap of 7.94B as of 2022 and a return on equity of 9.42%. Kangji’s products are used in a variety of surgical procedures, including laparoscopic, thoracic, and urological surgery. The company’s products are sold in over 30 countries worldwide.
– Formosa Optical Technology Co Ltd ($TPEX:5312)
Formosa Optical Technology Co Ltd is a leading manufacturer of optical fiber and fiber-optic cable products. The company has a market cap of 3.46B as of 2022 and a return on equity of 7.45%. Formosa Optical Technology Co Ltd is a publicly traded company listed on the Taiwan Stock Exchange.
WARBY PARKER reported its financial results for the second quarter of its FY2023, with total revenue increasing 11.0% from the same period last year to USD 166.1 million and a net income of -15.9 million, a considerable improvement from -32.2 million the previous year. Investors may be encouraged by the company’s recent financial results and the growing revenue and profitability. At the same time, however, stock prices moved down the same day. Investors may wish to carry out further analysis to understand the company’s performance and potential for future growth before making an investment decision.